Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Akcea Therapeutics Appoints CMO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Akcea Therapeutics Appoints CMO

William Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products.

By: Contract Pharma

Contract Pharma Staff

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., has appointed William Andrews, MD, FACP, as chief medical officer, effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company’s two commercial-stage products TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O’Dea, MB, BCh, BAO, FRCP(C), will serve as an advisor to the company to ensure a smooth transition.

Dr. Andrews brings two decades of life sciences experience in clinical development, medical affairs and medical/commercial strategy, including more than 13 years in rare diseases, and seven product launches. Most recently he served as chief medical officer at Acer Therapeutics, where he managed and led clinical development programs for rare diseases including Vascular Ehlers-Danlos syndrome, a fatal connective tissue disorder, and rare metabolic and oncology disorders.

“We are pleased to have Will join our leadership team as we continue to optimize our commercial and business strategies for TEGSEDI and WAYLIVRA and to progress our promising pipeline of novel drugs positioned to address major areas of unmet need in global health. His depth of experience in rare diseases will be especially valuable during this pivotal time at the company,” said Damien McDevitt, Ph.D., chief executive officer at Akcea. “On behalf of the entire team and board, I also want to thank Louis for his years of dedicated service to Akcea and helping position us well for future successes.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters